Sanofi-Aventis SA and Belgian biotech drugmaker UCB"s once-daily allergy medication Xyzal [levocetirizine dihydrochloride], has received FDA approval for children as young as six months. It has been approved to treat indoor allergies and hives in children six months and older as well as for outdoor allergies in children older than two.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지